|

BGB-43395 Clinical Trials

5 actively recruiting trials across 3 locations

▲ +1 trial since May 2026

Pipeline

Phase 1: 4Phase 3: 1

Top Sponsors

  • BeOne Medicines4
  • BeiGene1

Indications

  • Cancer5
  • Breast Cancer4
  • Hormone Receptor Positive Breast Cancer3
  • Advanced Solid Tumor3
  • Metastatic Breast Cancer2

Newport Beach, California2 trials

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Hoag Memorial Presbyterian

Phase 1
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Hoag Memorial Presbyterian

Phase 1

Other1 trial

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Phase 3

Birmingham, Alabama1 trial

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

University of Alabama At Birmingham Hospital

Phase 1

Denver, Colorado1 trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.